Syndrome Hypertension Associated With the CREST ...

Pulmonary Edema Caused by Inhaled Nitric Oxide Therapy in Two Patients With Pulmonary Hypertension Associated With the CREST Syndrome * Ioana R. Preston, James R. Klinger, Jeanne Houtchens, David Nelson, Sangeeta Mehta and Nicholas S. Hill Chest 2002;121;656-659 DOI 10.1378/chest.121.2.656 The online version of this article, along with updated information and services can be found online on the World Wide Web at: http://chestjournal.chestpubs.org/content/121/2/656.full.html

Chest is the official journal of the American College of Chest Physicians. It has been published monthly since 1935. Copyright2002by the American College of Chest Physicians, 3300 Dundee Road, Northbrook, IL 60062. All rights reserved. No part of this article or PDF may be reproduced or distributed without the prior written permission of the copyright holder. (http://chestjournal.chestpubs.org/site/misc/reprints.xhtml) ISSN:0012-3692

Downloaded from chestjournal.chestpubs.org by guest on July 14, 2011 © 2002 American College of Chest Physicians

monary hypertension: a diagnostic dilemma. Chest 1976; 69:229 –230 4 Seckl MJ, Rustin GJS, Newlands ES, et al. Pulmonary embolism, pulmonary hypertension, and choriocarcinoma. Lancet 1991; 338:1313–1315 5 Trubenbach J, Pereira PL, Huppert PE, et al. Primary choriocarcinoma of the pulmonary artery mimicking pulmonary embolism. Br J Radiol 1997; 70:843– 845 6 Savage P, Roddie M, Seckl MJ. A 28-year-old woman with a pulmonary embolus. Lancet 1998; 352:30

Pulmonary Edema Caused by Inhaled Nitric Oxide Therapy in Two Patients With Pulmonary Hypertension Associated With the CREST Syndrome* Ioana R. Preston, MD; James R. Klinger, MD, FCCP; Jeanne Houtchens, BS, RN; David Nelson, CRT; Sangeeta Mehta, MD; and Nicholas S. Hill, MD, FCCP

Pulmonary arterial hypertension (PAH) is commonly associated with the CREST (calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) syndrome. Inhaled nitric oxide (iNO) is often used to assess acute vasoresponsiveness in patients with PAH, and reports of adverse reactions have been infrequent. We describe two of nine patients with PAH and CREST syndrome who had pulmonary edema develop during acute iNO testing. This complication was not encountered in the 46 patients with other forms of PAH tested with iNO. We suggest that iNO should be used with caution, if at all, to test acute vasoreactivity in patients with CREST syndrome. (CHEST 2002; 121:656 – 659) Key words: CREST; epoprostenol; nitric oxide; pulmonary edema; pulmonary hypertension; scleroderma; vasodilators Abbreviations: CREST ⫽ calcinosis, Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia; iNO ⫽ inhaled nitric oxide; PAH ⫽ pulmonary arterial hypertension

ulmonary arterial hypertension (PAH) occurs in up to P 50% of patients with the limited form of progressive

systemic sclerosis, known as the CREST (calcinosis, *From the Division of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital and Brown University School of Medicine, Providence, RI. This study was supported by the National Heart, Lung, and Blood Institute grants HL-45050 (Dr. Hill) and HL-02613 (Dr. Klinger). Manuscript received April 6, 2001; revision accepted June 27, 2001. Corresponding to: Nicholas S. Hill, MD, FCCP, Division of Pulmonary, Critical Care and Sleep Medicine, Rhode Island Hospital, 593 Eddy St, Providence, RI 02903; e-mail: [email protected]

Raynaud phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) syndrome,1 and adversely affects prognosis.2 Uncontrolled studies3,4 and a randomized trial5 have reported favorable responses to long-term epoprostenol (prostacyclin) infusion in these patients, which led to the approval of epoprostenol by the US Food and Drug Administration in 1999 for use in PAH associated with connective tissue disease. Inhaled nitric oxide (iNO), by virtue of its rapid inactivation by hemoglobin and paucity of systemic side effects, has been considered an ideal agent for testing acute vasoreactivity 6 in patients with PAH of various etiologies. It has been reported to cause pulmonary edema in patients with congestive heart failure,7 but not in patients with PAH. We report two of a total of nine patients with the CREST syndrome who developed pulmonary edema during acute iNO testing. This complication was not encountered in the 46 patients with other forms of PAH who underwent acute vasodilator trials at our hospital during the same time period.

Results Between 1996 and 2000, 56 patients with PAH underwent acute vasodilator testing at Rhode Island Hospital, a teaching affiliate of Brown Medical School. The study protocol was approved by the Committee for the Protection of Human Subjects at Rhode Island Hospital, and all patients gave written consent. Patients were catheterized if they had progressive symptoms of dyspnea on exertion and an estimated peak pulmonary artery pressure ⬎ 40 mm Hg by echocardiography. During right-heart catheterization, iNO was delivered sequentially at concentrations of 5, 10, 20, and 40 ppm together with supplemental oxygen administered by tight-fitting face mask. Nitric dioxide levels were measured continuously and were within normal limits. iNO was followed by an epoprostenol infusion starting at 1 ng/kg/min and increased by 1 ng/kg every 15 min until systemic effects such as flushing, nausea, jaw pain, headache, or hypotension occurred. Hemodynamic measurements were made at baseline and after each dose of vasodilator. A favorable acute response was considered to be a ⱖ 20% decrease in pulmonary vascular resistance. Ten patients had PAH associated with the CREST syndrome. Of these, seven of eight patients administered epoprostenol and six of nine patients administered iNO had favorable responses. All six responders to iNO also had a favorable response to epoprostenol, whereas one patient responded to epoprostenol but not to iNO. Of the nine patients tested with iNO, acute pulmonary edema developed in two patients. None of the 46 patients with other forms of PAH (primary pulmonary hypertension, PAH associated with cirrhosis, HIV, systemic lupus erythematosus, secondary to thromboembolic disease, sarcoidosis, obstructive sleep apnea, or chronic obstructive lung disease) had pulmonary edema develop during acute vasodilator testing.

Case 1 A 70-year-old woman with a 20-year history of CREST syndrome presented with progressive dyspnea on exertion. She had systemic hypertension, glaucoma, a hiatal hernia, and a history of sarcoidosis diagnosed 24 years previously by mediastinoscopy, but with no evidence of active disease. Medications included warfarin, spironolactone, losartan, nifedipine, and supplemental nasal oxygen at 5 L/min. Physical examination showed mild facial and manual telangiectasias, clear lungs, increased P2, and trace ankle edema.

656

Selected Reports


Spirometry results and lung volumes were normal on pulmonary function testing, and diffusion capacity of the lung for carbon monoxide was 16% of predicted. Arterial blood gas measures obtained with the patient breathing oxygen at 3 L/min were as follows: pH, 7.34; Po2, 52 mm Hg; and Pco2, 39 mm Hg. CT of the chest showed minimal ground-glass opacities. A left-heart catheterization revealed normal coronary arteries and left ventricular function. Hemodynamic measurements during right-heart catheterization are shown in Table 1. The test was performed while the patient breathed 40% oxygen, and oxygen saturation was maintained at ⬎ 90%. During iNO administration at 40 ppm, severe dyspnea, tachypnea, and tachycardia developed, and oxygen saturation fell to 85%. Lung auscultation revealed new bilateral rales. An ECG did not show ischemic changes. Pulmonary artery wedge pressure and pulmonary artery pressure remained unchanged. iNO was immediately discontinued, and sublingual nitroglycerin and IV morphine and furosemide were administered, with rapid symptomatic improvement. A chest radiograph obtained after symptomatic improvement showed mild interstitial edema. The next morning, epoprostenol infusion was initiated that was tolerated up to 4 ng/kg/min (Table 1). Treatment with epoprostenol was followed by an IV nitroglycerin infusion up to 80 ␮g/min that was discontinued because of systemic hypotension. The patient was discharged home with a continuous subcutaneous infusion of prostacyclin (UT-15; United Therapeutics; Research Triangle Park, NC) and has remained symptomatically improved for 6 months.

Pulmonary function tests showed a total lung capacity of 52% of predicted and a diffusion capacity of the lung for carbon monoxide of 26% of predicted. Oxygen saturation of hemoglobin with the patient at rest and receiving oxygen supplementation at 4 L/min was 94%. Chest radiography revealed increased markings at the lung bases and small pleural effusions bilaterally (Fig 1, top). Echocardiography revealed a peak pulmonary artery pressure of 67 mm Hg and normal left ventricular function. Hemodynamic measurements during heart catheterization with the patient breathing 35% oxygen are shown in Table 1. While receiving iNO at 20 ppm, acute dyspnea, tachypnea, and increased bilateral rales developed. Oxygen saturation was maintained at 90% after the fraction of inspired oxygen was increased to 100% by face mask. Chest radiography showed increased interstitial markings compatible with pulmonary edema (Fig 1, middle), but pulmonary artery wedge pressure remained unchanged. After prompt discontinuation of iNO, IV morphine and furosemide were administered and symptoms improved rapidly. A follow-up chest radiograph obtained 7 h after the episode showed improvement of the interstitial markings (Fig 1, bottom). The next day, epoprostenol infusion was administered only up to 2 ng/kg/min, due to systemic hypotension. The patient was discharged home receiving epoprostenol at 1 ng/kg/min and had a transient improvement in her dyspnea. She died 4 months later of intractable right-heart failure. Pathologic examination of the lungs showed interstitial fibrosis and intimal thickening of pulmonary arteries, compatible with her diagnosis of CREST syndrome. There was no evidence of left-heart or pulmonary venous disease.

Discussion

Case 2

We observed symptoms and signs of acute pulmonary edema during iNO testing in two patients with severe PAH associated with the CREST syndrome. No such reaction developed in 46 other patients with PAH of different etiologies undergoing vasodilator testing with iNO or epoprostenol. Acute pulmonary edema has previously been reported in patients with scleroderma during short-term8 –10 and

A 57-year-old woman with a 24-year history of CREST syndrome and a 2-year history of progressive dyspnea on exertion was referred for acute vasodilator testing. Her medications included nifedipine and omeprazole and supplemental nasal oxygen at 4 to 5 L/min. Physical examination revealed facial telangiectasias, few bibasilar rales on lung auscultation, a prominent right ventricular impulse, an increased P2, a holosystolic murmur at the left lower sternal border, trace ankle edema, and sclerodactyly.

Table 1—Hemodynamic Characteristics of the Two Patients at Baseline and During Short-term Vasodilator Testing* Patient No.

SBP, mm Hg

PAP, mm Hg

mPAP, mm Hg

PVR, dyne 䡠 s 䡠 cm⫺5

PAWP, mm Hg

iNO baseline iNO, 5 ppm iNO, 10 ppm iNO, 20 ppm iNO, 40 ppm† Epo baseline Epo, 3 ng/kg/min Epo, 4 ng/kg/min

119/60 121/48 112/47 114/44 120/68 108/38 96/52 101/52

98/37 88/32 87/31 87/31 88/30 88/31 70/26 74/27

61 54 53 52 52 53 43 46

1,054 755 798 818

iNO baseline iNO, 5 ppm iNO, 10 ppm iNO, 20 ppm† Epo baseline Epo, 1 ng/kg/min Epo, 2 ng/kg/min

110/94 98/67 90/69 135/73 105/97 97/66 84/59

86/34 72/25 78/29 85/34 81/30 81/47 81/30

51 41 45 51 47 47 47

945 954 867 945 1,020 921

Vasodilator

CO, L/min

SVR, dyne 䡠 s 䡠 cm⫺5

12 13 8 8 7 5 6 7

3.64 4.34 4.51 4.30

1,472 1,198 1,081 1,227

3.39 4.17 4.45

1,297 1,208 1,150

12 10 11 12 10 9 9

3.30 3.10 3.50 3.30 2.90 3.30

2,182 1,935 1,600 2,109 2,538 1,503

1

1,132 690 701

2

*SBP ⫽ systemic BP; PAP ⫽ pulmonary artery pressure; mPAP ⫽ mean pulmonary artery pressure; PVR ⫽ pulmonary vascular resistance; PAWP ⫽ pulmonary arterial wedge pressure; CO ⫽ cardiac output; SVR ⫽ systemic vascular resistance; Epo ⫽ epoprostenol. †Dose of iNO at which pulmonary edema occurred.

CHEST / 121 / 2 / FEBRUARY, 2002


657

long-term4,11 epoprostenol administration, but not with iNO. Two of the patients who had pulmonary edema develop during short-term epoprostenol administration8,9 had an increase in pulmonary artery wedge pressure, and the third patient10 had evidence of pulmonary venoocclusive disease at autopsy. Long-term epoprostenol infusion was associated with the development of pulmonary edema in a patient with scleroderma and pulmonary capillary hemangiomatosis,11 a condition in which pulmonary edema has been previously described in association with epoprostenol treatment.12 The only previous report of pulmonary edema associated with acute iNO administration was in three patients with severe refractory congestive heart failure and baseline elevated pulmonary capillary wedge pressures that increased further with iNO.7 However, other investigators13 have found no influence on left ventricular diastolic function in response to iNO in patients with mild congestive heart failure. Earlier reports7,9 of pulmonary edema associated with vasodilators proposed either a cardiogenic mechanism, in which increased blood flow to the left heart raised left-sided filling pressure, or pulmonary capillary pressure increased in the presence of fixed venous obstruction, as in pulmonary veno-occlusive disease.14 Although the presence of pulmonary veno-occlusive disease cannot be excluded in our first case in the absence of a postmortem examination, we speculate that a noncardiogenic form of hydrostatic pulmonary edema developed in our patients. The normal pulmonary artery wedge pressures that remained unchanged during the acute episode support a noncardiogenic mechanism, and the rapid reversal of symptoms supports a hydrostatic cause. Furthermore, normal levels of nitrogen dioxide, as well as reversal of the pulmonary edema within hours, makes an alteration of capillary permeability by toxic byproducts of iNO less likely. Therefore, we postulate that in our patients, iNO caused a temporary increase in pulmonary capillary hydrostatic pressure, perhaps by dilating precapillary pulmonary arteries more than the postcapillary pulmonary venules. Larger vessels distal to the small pulmonary veins probably remained unaffected, hence the normal pulmonary artery wedge pressure. Interestingly, the nitrovasodilator nitroglycerin and epoprostenol were tolerated, suggesting a different distribution of their vascular effects in the pulmonary circulation. Considering that epoprostenol is at least as sensitive as iNO in detecting acute pulmonary vasoreactivity in patients with scleroderma,3 we suggest that it be used in preference to iNO for vasodilator testing. If it is to be used at all in these patients, iNO should be administered at low concentrations (ⱕ 10 ppm) during careful monitoring.

References

Figure 1. Chest radiographs of Case 2 obtained 2 h before (top), during (middle), and after (bottom) the episode of acute pulmonary edema.

1 Ungerer RG, Tashkin DP, Furst D, et al. Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis. Am J Med 1983; 75:65–74 2 Salerni R, Rodnan GP, Leon DF, et al. Pulmonary hypertension in the CREST syndrome variant of progressive systemic sclerosis (scleroderma). Ann Intern Med 1977; 86:394 –399 3 Klings ES, Hill NS, Ieong MH, et al. Systemic sclerosisassociated pulmonary hypertension: short- and long-term

658

Selected Reports


4

5

6

7 8

9 10

11

12

13

14

effects of epoprostenol (prostacyclin). Arthritis Rheum 1999; 42:2638 –2645 Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13:1351–1356 Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000; 132:425– 434 Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12:265–270 Bocchi EA, Bacal F, Auler JO Jr, et al. Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure. Am J Cardiol 1994; 74:70 –72 Farber HW, Graven KK, Kokolski G, et al. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma. J Rheumatol 1999; 26:1195–1196 Strange C, Bolster M, Mazur J, et al. Hemodynamic effects of epoprostenol in patients with systemic sclerosis and pulmonary hypertension. Chest 2000; 118:1077–1082 Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results of a randomized trial. Ann Intern Med 1990; 112:485– 491 Gugnani MK, Pierson C, Vanderheide R, et al. Pulmonary edema complicating prostacyclin therapy in pulmonary hypertension associated with scleroderma: a case of pulmonary capillary hemangiomatosis. Arthritis Rheum 2000; 43:699–703 Humbert M, Maitre S, Capron F, et al. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157:1681–1685 Hayward CS, Kalnins WV, Rogers P, et al. Left ventricular chamber function during inhaled nitric oxide in patients with dilated cardiomyopathy. J Cardiovasc Pharmacol 1999; 34: 749 –754 Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998; 113:237–240

Diffuse Panbronchiolitis* A Treatable Sinobronchial Disease in Need of Recognition in the United States Padmanabhan Krishnan, MBBS, FCCP; Rajeeve Thachil, MBBS; and Virgilio Gillego, MD

Diffuse panbronchiolitis (DPB) is a progressive inflammatory disease, well recognized in Japan, characterized by sinusitis and obstructive small airway disease; if left untreated, it progresses to bronchiectasis, respiratory failure, and death. Treatment using low-dose erythromycin has proven to be highly efficacious. Lack of familiarity with DPB in the United States may result in the failure to correctly diagnose

and treat this disorder. We describe a Cambodian man in whom the characteristic imaging and histologic features of DPB were elicited but not recognized in spite of evaluation at a referral center. When DPB was diagnosed 6 years later, he was in respiratory failure, but made an excellent recovery once erythromycin therapy was instituted. We report this case to increase physician awareness of DPB as a cause of sinobronchial disease and discuss its diagnostic features so that the disease is recognized and treated without delay. (CHEST 2002; 121:659 – 661) Key words: diffuse panbronchiolitis; long-term low-dose macrolide therapy; sinobronchial disease Abbreviations: DPB ⫽ diffuse panbronchiolitis; HLA ⫽ human leukocyte antigen; HRCT ⫽ high-resolution CT

iffuse panbronchiolitis (DPB) is an idiopathic inflamD matory disease that is not uncommon in Japan,

Korea, and China. It is characterized by progressive suppurative and obstructive airway disease, first involving the sinuses and respiratory bronchioles, which, left untreated, progresses to bronchiectasis, respiratory failure, and death.1–3 Its distinctive imaging and histologic features, the presence of sinusitis, and the isolation of Haemophilus influenzae and Pseudomonas aeruginosa in the sputum should enhance disease recognition.1–3 If DPB is left untreated, only 12 to 25% of patients survive 10 years.4 The long-term use of low-dose erythromycin therapy has proven to be highly effective in treating patients with DPB. Reported mainly among Asian patients, and primarily Japanese patients, the disease has been reported only rarely in Europe and the United States and is, therefore, unfamiliar to physicians in the West.3 This report demonstrates this fact and re-emphasizes that unless DPB is included in the differential diagnosis of sinobronchial disorders, progressive bronchiolitis, bronchiectasis, and unexplained progressive obstructive airway disease, this treatable disorder will remain underrecognized in the United States.3

Case Report A 39-year-old unmarried Cambodian man complained of progressive exertional dyspnea and productive cough, which he had first noticed 10 years ago in Cambodia. These symptoms progressively worsened while in the United States, and 6 years ago he received a diagnosis of chronic interstitial pneumonitis after undergoing an open lung biopsy, which was performed at another institution. He refused lung transplantation after treatment with prednisone and azathioprine proved unsuccessful. Exertional dyspnea and productive cough worsened over the next 4 years to the point that he was dyspneic on minimal exertion when he was first seen by us. A physical examination revealed a cachectic man who was *From the Departments of Pulmonary Medicine (Drs. Krishnan and Thachil) and Radiology (Dr. Gillego), Coney Island Hospital, Brooklyn, NY. Manuscript received April 10, 2001; revision accepted July 25, 2001. Correspondence to: Padmanabhan Krishnan, MBBS, FCCP, Associate Director, Department of Pulmonary Medicine, Coney Island Hospital, 2601 Ocean Pkwy, Brooklyn, NY 11235 CHEST / 121 / 2 / FEBRUARY, 2002


659

Pulmonary Edema Caused by Inhaled Nitric Oxide Therapy in Two Patients With Pulmonary Hypertension Associated With the CREST Syndrome* Ioana R. Preston, James R. Klinger, Jeanne Houtchens, David Nelson, Sangeeta Mehta and Nicholas S. Hill Chest 2002;121; 656-659 DOI 10.1378/chest.121.2.656 This information is current as of July 14, 2011 Updated Information & Services Updated Information and services can be found at: http://chestjournal.chestpubs.org/content/121/2/656.full.html References This article cites 12 articles, 6 of which can be accessed free at: http://chestjournal.chestpubs.org/content/121/2/656.full.html#ref-list-1 Cited Bys This article has been cited by 2 HighWire-hosted articles: http://chestjournal.chestpubs.org/content/121/2/656.full.html#related-urls Permissions & Licensing Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://www.chestpubs.org/site/misc/reprints.xhtml Reprints Information about ordering reprints can be found online: http://www.chestpubs.org/site/misc/reprints.xhtml Citation Alerts Receive free e-mail alerts when new articles cite this article. To sign up, select the "Services" link to the right of the online article. Images in PowerPoint format Figures that appear in CHEST articles can be downloaded for teaching purposes in PowerPoint slide format. See any online figure for directions.
